

111TH CONGRESS
2D SESSION

H. R. 2408

IN THE SENATE OF THE UNITED STATES

NOVEMBER 15, 2010

Received; read twice and referred to the Committee on Health, Education,
Labor, and Pensions

AN ACT

To expand the research and awareness activities of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Centers for Disease Control and Prevention with respect to scleroderma, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Scleroderma Research
3 and Awareness Act of 2010”.

4 **SEC. 2. NATIONAL INSTITUTE OF ARTHRITIS AND MUS-**
5 **CULOSKELETAL AND SKIN DISEASES;**
6 **SCLERODERMA RESEARCH EXPANSION.**

7 Part B of title IV of the Public Health Service Act
8 (42 U.S.C. 284 et seq.) is amended by adding at the end
9 the following:

10 **“SEC. 409K. SCLERODERMA RESEARCH.**

11 “The Director of NIH may expand, intensify, and co-
12 ordinate the activities of the National Institutes of Health
13 with respect to scleroderma, with particular emphasis on
14 the following:

15 “(1) Research focused on the etiology of
16 scleroderma and the development of new treatment
17 options.

18 “(2) Clinical research to evaluate new treat-
19 ments options.

20 “(3) Basic research on the relationship between
21 scleroderma and secondary conditions such as pul-
22 monary hypertension, gastroparesis, Raynaud’s phe-
23 nomenon, Sjögren’s Syndrome, and other diseases as
24 determined by the Director.”.

1 **SEC. 3. PROMOTING PUBLIC AWARENESS OF**
2 **SCLERODERMA.**

3 Part P of title III of the Public Health Service Act
4 (42 U.S.C. 280g et seq.) is amended by adding at the end
5 the following:

6 **“SEC. 399V-5. PROMOTING PUBLIC AWARENESS OF**
7 **SCLERODERMA.**

8 “The Secretary may carry out an educational cam-
9 paign to increase public awareness of scleroderma. Print,
10 video, and Web-based materials distributed through this
11 campaign may include—

12 “(1) basic information on scleroderma and its
13 symptoms; and

14 “(2) information on—

15 “(A) the incidence and prevalence of
16 scleroderma;

17 “(B) diseases and conditions affiliated with
18 scleroderma; or

19 “(C) the importance of early diagnosis and
20 treatment of scleroderma.”.

Passed the House of Representatives September 30
(legislative day September 29), 2010.

Attest: LORRAINE C. MILLER,
Clerk.